New Indications. (a) As provided in the Ex-US Agreement, Protalix shall notify the Steering Committee, at least every six (6) months during the Term, of any material updates with respect to any material Development activities, with respect to the Licensed Product for a New Indication (a “New Use”). (b) [***] (c) [***] [***] Redacted pursuant to confidential treatment request.
Appears in 1 contract
Sources: Exclusive License and Supply Agreement (Protalix BioTherapeutics, Inc.)
New Indications. (a) As provided in the Ex-US Agreement, Protalix shall notify the Steering Committee, at least every six (6) months during the Term, of any material updates with respect to any material Development activities, with respect to the Licensed Product for a New Indication (a “New Use”).
(b) [***].
(c) [***] [***] Redacted pursuant to confidential treatment request].
Appears in 1 contract
Sources: Exclusive License and Supply Agreement (Protalix BioTherapeutics, Inc.)